Upstream files patent for ovarian cancer biomarkers

By Lisa Kerner

Charlotte, N.C., Sept. 13 - Upstream Biosciences Inc. filed a provisional patent application with the U.S. Patent and Trademark Office for certain ovarian cancer biomarkers to determine a genetic risk of developing ovarian cancer, the fifth leading cancer death among women.

"We look forward to working with leading cancer researchers to further validate our discoveries in ovarian cancer," chief executive officer Joel Bellenson said in a company news release.

Vancouver-based Upstream develops genetic-based diagnostics for cancer susceptibility and drug response.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.